The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...